Connor, Clark & Lunn Investment Management Ltd. Collegium Pharmaceutical, Inc Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	SELL	$31.23 - $40.91 $931,216 - $1.22 Million	-29,818 Reduced 77.67%	8,573 $332,000
Q4 2023 Feb 09, 2024	SELL	$21.16 - $30.8 $934,235 - $1.36 Million	-44,151 Reduced 53.49%	38,391 $1.18 Million
Q3 2023 Nov 13, 2023	BUY	$21.23 - $24.28 $85,896 - $98,236	4,046 Added 5.15%	82,542 $1.84 Million
Q2 2023 Aug 10, 2023	BUY	$21.06 - $24.0 $774,986 - $883,176	36,799 Added 88.25%	78,496 $1.69 Million
Q1 2023 May 09, 2023	BUY	$23.0 - $29.88 $959,031 - $1.25 Million	41,697 New	41,697 $1 Million
Q2 2022 Aug 05, 2022	SELL	$14.22 - $20.88 $268,502 - $394,256	-18,882 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$17.2 - $22.5 $324,770 - $424,845	18,882 New	18,882 $384,000
Q3 2019 Nov 13, 2019	SELL	$10.16 - $13.28 $105,664 - $138,112	-10,400 Closed	0 $0
Q2 2019 Aug 07, 2019	BUY	$10.62 - $16.59 $110,447 - $172,536	10,400 New	10,400 $137,000

Others Institutions Holding COLL

# of Institutions

249

Shares Held

36.2M

Call Options Held

100K

Put Options Held

21.1K

Black Rock Inc. New York, NY

5.79M
Shares

$189 Million
0.0% of portfolio
Eventide Asset Management, LLC Boston, MA

2.64M
Shares

$85.9 Million
1.79% of portfolio
Vanguard Group Inc Valley Forge, PA

2.35M
Shares

$76.5 Million
0.0% of portfolio
Pacer Advisors, Inc. Malvern, PA

2.14M
Shares

$69.8 Million
0.15% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

1.66M
Shares

$54 Million
0.1% of portfolio

View Full List

About COLLEGIUM PHARMACEUTICAL, INC

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.11B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

More about COLL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account